Aptose Biosciences Inc (APTO)

[dcaf7]

I remember, some years ago you already had a knee replacement. Is it the other knee? I which you a painless recovery. As for olutasidenib, it is IDH1 inhibitor and at reasonable concentrations should not act directly on protein kinases. A product of mutated IDH, 2-hydroxyglutarate, interferes DNA and histone demethylation and therefore, dysregulates expression of many genes, including, possibly, some TKs. I think, your question is about upregulation of tyrosine kinase PDGFRA. I agree that this effect of IDH1 mutation should be considered but I am not sure that it is a key abnormality leading to AML in patients. BTW, dasatinib is an inhibitor with a broad specificity.